Assertio (ASRT) Competitors $0.61 -0.01 (-1.72%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.62 +0.01 (+2.39%) As of 04/17/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ASRT vs. PVLA, OLMA, CMPX, IMMP, DRUG, FHTX, MBX, ITOS, CRVS, and CKPTShould you be buying Assertio stock or one of its competitors? The main competitors of Assertio include Palvella Therapeutics (PVLA), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), Immutep (IMMP), Bright Minds Biosciences (DRUG), Foghorn Therapeutics (FHTX), MBX Biosciences (MBX), iTeos Therapeutics (ITOS), Corvus Pharmaceuticals (CRVS), and Checkpoint Therapeutics (CKPT). These companies are all part of the "pharmaceutical products" industry. Assertio vs. Palvella Therapeutics Olema Pharmaceuticals Compass Therapeutics Immutep Bright Minds Biosciences Foghorn Therapeutics MBX Biosciences iTeos Therapeutics Corvus Pharmaceuticals Checkpoint Therapeutics Palvella Therapeutics (NASDAQ:PVLA) and Assertio (NASDAQ:ASRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, community ranking, risk, profitability, dividends, media sentiment and valuation. Which has preferable earnings & valuation, PVLA or ASRT? Palvella Therapeutics has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalvella Therapeutics$42.81M6.27-$24.54M-$12.10-2.01Assertio$124.96M0.47-$331.94M-$0.23-2.65 Which has more volatility & risk, PVLA or ASRT? Palvella Therapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Does the media favor PVLA or ASRT? In the previous week, Palvella Therapeutics had 10 more articles in the media than Assertio. MarketBeat recorded 11 mentions for Palvella Therapeutics and 1 mentions for Assertio. Palvella Therapeutics' average media sentiment score of 0.93 beat Assertio's score of 0.59 indicating that Palvella Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assertio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is PVLA or ASRT more profitable? Palvella Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -54.46%. Assertio's return on equity of 3.79% beat Palvella Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palvella TherapeuticsN/A -80.93% -59.55% Assertio -54.46%3.79%1.81% Does the MarketBeat Community believe in PVLA or ASRT? Assertio received 99 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 59.89% of users gave Assertio an outperform vote. CompanyUnderperformOutperformPalvella TherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesAssertioOutperform Votes11259.89% Underperform Votes7540.11% Do analysts prefer PVLA or ASRT? Palvella Therapeutics currently has a consensus price target of $44.43, indicating a potential upside of 82.38%. Assertio has a consensus price target of $2.75, indicating a potential upside of 350.52%. Given Assertio's higher probable upside, analysts clearly believe Assertio is more favorable than Palvella Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palvella Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Assertio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of PVLA or ASRT? 40.1% of Palvella Therapeutics shares are owned by institutional investors. Comparatively, 49.0% of Assertio shares are owned by institutional investors. 6.4% of Palvella Therapeutics shares are owned by insiders. Comparatively, 3.2% of Assertio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryPalvella Therapeutics beats Assertio on 10 of the 19 factors compared between the two stocks. Get Assertio News Delivered to You Automatically Sign up to receive the latest news and ratings for ASRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASRT vs. The Competition Export to ExcelMetricAssertioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.46M$6.44B$5.29B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.846.8821.7117.77Price / Sales0.47231.36379.3997.65Price / Cash1.1265.6738.2234.64Price / Book0.425.916.443.98Net Income-$331.94M$142.72M$3.21B$247.44M7 Day Performance-1.55%4.33%2.81%1.82%1 Month Performance-14.99%-12.80%-8.67%-6.98%1 Year Performance-19.05%-9.71%11.32%1.49% Assertio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASRTAssertio2.0904 of 5 stars$0.61-1.7%$2.75+350.5%-21.7%$58.46M$124.96M-0.8420PVLAPalvella Therapeutics3.6345 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AOLMAOlema Pharmaceuticals2.8019 of 5 stars$3.18-2.2%$27.67+770.0%-58.7%$217.30MN/A-1.4570Short Interest ↓Positive NewsCMPXCompass Therapeutics3.42 of 5 stars$1.57+7.5%$13.38+751.9%+14.4%$217.10M$850,000.00-4.2420Short Interest ↑Gap DownIMMPImmutep1.0559 of 5 stars$1.42-5.3%$8.50+498.6%-31.9%$206.69M$5.14M0.002,021Gap DownDRUGBright Minds Biosciences2.4889 of 5 stars$29.25-8.7%$84.33+188.3%+2,804.4%$206.04MN/A-172.05N/ANews CoverageGap UpFHTXFoghorn Therapeutics2.2148 of 5 stars$3.68+7.0%$13.17+257.8%-34.3%$204.65M$22.60M-1.92120Positive NewsMBXMBX Biosciences2.3772 of 5 stars$6.00-0.7%$37.25+520.8%N/A$200.54MN/A0.0036Gap UpITOSiTeos Therapeutics2.2071 of 5 stars$5.25-2.6%$25.75+390.5%-39.0%$200.52M$35M-1.6790Short Interest ↑Positive NewsCRVSCorvus Pharmaceuticals2.4667 of 5 stars$2.91+2.1%$15.67+438.4%+138.2%$198.28MN/A-3.1330Positive NewsGap UpCKPTCheckpoint Therapeutics1.622 of 5 stars$3.99-0.5%$4.33+8.6%+141.9%$194.84M$41,000.00-2.1710 Related Companies and Tools Related Companies Palvella Therapeutics Competitors Olema Pharmaceuticals Competitors Compass Therapeutics Competitors Immutep Competitors Bright Minds Biosciences Competitors Foghorn Therapeutics Competitors MBX Biosciences Competitors iTeos Therapeutics Competitors Corvus Pharmaceuticals Competitors Checkpoint Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASRT) was last updated on 4/18/2025 by MarketBeat.com Staff From Our Partners🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASRT Stock Free ASRT Stock Alerts